Exploring Pharmacokinetics and Safety for Drugs Targeting the Gut

April 1, 2022 PAO-04-22-R250-03

In another interview from Pharma's Almanac's the Road to 50 States road trip campaign, Bill Thelin, Chief Science Officer at Altis Biosystems, talks to Nigel about the company's innovative RepliGut system and how that system allows Altis to conduct very detailed studies on drug pharmacokinetics and safety.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Altis Biosystems

Altis’s mission is to develop, manufacture and sell innovative services and research tools to accelerate drug development. Their goal is to reduce the time and cost of drug development with in vitro platforms that more accurately reflect native human biology. Altis considers its intestinal platform to be the next generation for in vitro testing during drug development.

Q: